Bridgewater Associates LP Decreases Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Bridgewater Associates LP trimmed its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 28.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,463 shares of the company’s stock after selling 1,409 shares during the quarter. Bridgewater Associates LP’s holdings in TransMedics Group were worth $216,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Norges Bank bought a new stake in shares of TransMedics Group in the 4th quarter worth approximately $22,861,000. Emerald Advisers LLC increased its holdings in TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock worth $23,176,000 after acquiring an additional 220,804 shares during the last quarter. FIL Ltd raised its position in shares of TransMedics Group by 28.0% in the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company’s stock valued at $62,372,000 after purchasing an additional 218,961 shares during the period. Principal Financial Group Inc. lifted its position in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares in the last quarter. Finally, Capital Fund Management S.A. lifted its holdings in TransMedics Group by 940.3% during the 4th quarter. Capital Fund Management S.A. now owns 125,880 shares of the company’s stock worth $7,849,000 after purchasing an additional 113,780 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

TransMedics Group stock opened at $88.24 on Monday. The stock’s 50 day moving average is $72.48 and its 200 day moving average is $78.99. The company has a market capitalization of $2.98 billion, a P/E ratio of 93.87 and a beta of 2.14. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TMDX shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.